GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Subjects must have confirmed diagnosis of aHCC (locally advanced or metastatic hepatocellular carcinoma) by radiography, histology and/or cytology, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and/or locoregional therapies (fibrolamellar, sarcomatoid HCC and mixed hepatocellular / cholangiocarcinoma subtypes are not eligible); * Have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy; * Have documented disease progression after or intolerance to first line treatment of immune checkpoint inhibitors(ICI) * Child-Pugh score ≤ 6 (Child-Pugh A) score within 7 days of first dose of study drug; * ECOG performance status: 0-1 within 7 days of first dose of study drug; * Have a predicted life expectancy of greater than 3 months; * Adequate hematologic and end-organ function functions of the important organs are confirmed. Exclusion Criteria: * Presence of tumor thrombus involving main trunk of portal vein (Vp4), inferior vena cava, cardiac involvement of HCC; * Subjects with untreated or incompletely treated varices with bleeding or high-risk for bleeding. Has had esophageal or gastric variceal bleeding within the last 6 months; * History of encephalopathy; * Has a known history of, or any evidence of central nervous system (CNS) metastases and/or carcinomatous meningitis; * Had history of a solid organ or hematologic transplant; * Has received locoregional therapy to liver (TACE, TAE, hepatic arterial infusion \[HAI\], radiation, radioembolization or ablation) within 4 weeks of start of study treatment. * Had prior systemic TKI treatment prior to start of study treatment; * Has received prior immune checkpoint inhibitors within 4 weeks of start of study treatment; * Has received Nivolumab in the first-line systemic therapy: * Active co-infection with: 1. Both hepatitis B and C as evidenced by positive HBV surface antigen or detectable HBV DNA and HCV RNA, OR 2. Hepatitis D infection in subjects with hepatitis B * Has an active bacterial or fungal infection requiring systemic therapy within 7 days prior to study drug dosing; * Has a known history of active tuberculosis (Bacillus Tuberculosis); * Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture; * Thrombotic or embolic events (except HCC tumor thrombus) within the past 6 months, such as cerebrovascular accident (including transient ischemic attacks), pulmonary embolism; If prior history of deep vein thrombosis (DVT) / (pulmonary embolism (PE), the subject needs to be on stable doses of anticoagulation with low molecular weight heparin or oral anticoagulant for at least two weeks; * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis; * Subjects with any other serious disease considered by the investigator not in the condition to enter into the trial;